The Terry Fox Foundation

Financial Statements
March 31, 2026

Independent Auditor's Report

To the Board of The Terry Fox Foundation:

Opinion

We have audited the financial statements of The Terry Fox Foundation (the "Foundation"), which comprise the statement of financial position as at March 31, 2026, and the statements of operations, changes in net assets and cash flows for the year then ended, and notes to the financial statements, including a summary of significant accounting policies.

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Foundation as at March 31, 2026, and the results of its operations and its cash flows for the year then ended in accordance with Canadian accounting standards for not-for-profit organizations.

Basis for Opinion

We conducted our audit in accordance with Canadian generally accepted auditing standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Foundation in accordance with the ethical requirements that are relevant to our audit of the financial statements in Canada, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with Canadian accounting standards for not-for-profit organizations, and for such internal control as management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is responsible for assessing the Foundation's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Foundation or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Foundation's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Canadian generally accepted auditing standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with Canadian generally accepted auditing standards, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Foundation's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Foundation to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Vancouver, British Columbia

July 7, 2026

MNP LLP

Chartered Professional Accountants

The Terry Fox Foundation

Statement of Financial Position

As at March 31, 2026

	2026 $	2025 $
Assets		
Current assets		
Cash and cash equivalents (note 3)	13,387,525	12,473,167
International funds held on behalf of the Foundation	365,228	444,552
Short-term investments (note 4)	34,560,812	37,385,569
Merchandise inventory (note 5)	1,085,844	637,599
Accounts receivable and other assets (note 6)	1,277,037	1,179,712
	50,676,446	52,120,599
Long-term investments (note 4)	43,331,330	40,000,000
Capital and intangible assets (note 7)	217,189	126,295
	94,224,965	92,246,894
Liabilities		
Current liabilities		
Accounts payable and accrued liabilities (note 8)	3,703,804	1,345,011
Deferred revenue (note 11)	50,000	111,164
	3,753,804	1,456,175
Liability for post-retirement benefits (note 10)	35,889	41,499
	3,789,693	1,497,674
Net Assets		
Invested in capital assets	217,189	126,295
Internally restricted (note 12)	43,331,330	40,000,000
Unrestricted	46,886,753	50,622,925
	90,435,272	90,749,220
	94,224,965	92,246,894

Commitments (notes 13 and 14)

Subsequent event (note 16)

Approved by the Board of Directors

Director

Director

The accompanying notes are an integral part of these financial statements.

The Terry Fox Foundation

Statement of Operations

For the year ended March 31, 2026

	2026 $	2025 $
Revenue		
Annual giving		
Canada	40,472,760	36,244,620
International	1,556,527	1,394,945
Bequests and memorials	537,531	1,775,634
Government student grants and other	102,369	27,371
Total fundraising revenue	42,669,187	39,442,570
Investment income, net (note 4)	6,438,229	6,837,385
Sale of merchandise	3,966,277	2,404,047
	53,073,693	48,684,002
Expenses		
Fundraising (note 9)	6,986,717	6,308,475
Administration	5,241,722	4,639,843
Total operating expenses	12,228,439	10,948,318
Cost of merchandise sold (note 5)	1,556,440	1,376,506
	13,784,879	12,324,824
Excess of revenue over expenses before distribution of funds	39,288,814	36,359,178
Distribution of funds and other charitable activities		
The Terry Fox Research Institute (note 8)	37,553,836	29,827,105
International cancer research organizations	1,524,419	1,217,601
Other distributions and charitable activities	524,507	678,052
	39,602,762	31,722,758
(Deficit) excess of revenue over expenses/distributions	(313,948)	4,636,420

The accompanying notes are an integral part of these financial statements.

The Terry Fox Foundation

Statement of Changes in Net Assets

For the year ended March 31, 2026

	Invested in capital assets $	Internally restricted $	Unrestricted $	Total $
Balance – March 31, 2025	126,295	40,000,000	50,622,925	90,749,220
Excess (deficiency) of revenue over expenses/distributions	(58,443)		(255,505)	(313,948)
Investment in capital assets	149,337	-	(149,337)	-
Interfund transfer (note 12)		3,331,330	(3,331,330)	
Balance – March 31, 2026	217,189	43,331,330	46,886,753	90,435,272

	Invested in capital assets $	Internally restricted $	Unrestricted $	Total $
Balance – March 31, 2024	39,899	40,000,000	46,072,901	86,112,800
Excess (deficiency) of revenue over expenses/distributions	(27,385)	-	4,663,805	4,636,420
Investment in capital assets	113,781	-	(113,781)	-
Balance – March 31, 2025	126,295	40,000,000	50,622,925	90,749,220

The accompanying notes are an integral part of these financial statements.

The Terry Fox Foundation

Statement of Cash Flows

For the year ended March 31, 2026

	2026 $	2025 $
Cash provided by (used in)		
Operating activities		
(Deficit) excess of revenue over expenses/distributions	(313,948)	4,636,420
Items not affecting cash		
Capital assets – amortization	58,443	27,385
Investment income reinvested	(4,651,663)	(4,270,385)
Change in unrealized gain on investments	(1,854,910)	(2,523,500)
Change in liability for post-retirement benefits	(5,610)	(7,556)
	(6,767,688)	(2,137,636)
Changes in non-cash operating working capital		
International funds held on behalf of the Foundation	79,324	(99,450)
Merchandise inventory	(448,245)	32,408
Accounts receivable and other assets	(97,325)	(432,109)
Accounts payable and accrued liabilities	2,358,793	241,361
Deferred revenue	(61,164)	(500,417)
	1,831,383	(2,895,843)
Investing activities		
Proceeds on sale of investments	6,000,000	1,000,000
Additions to capital assets	(149,337)	(113,781)
	5,850,663	886,219
Increase (decrease) in cash and cash equivalents	914,358	(2,009,624)
Cash and cash equivalents – Beginning of year	12,473,167	14,482,791
Cash and cash equivalents – End of year	13,387,525	12,473,167

The accompanying notes are an integral part of these financial statements.

1 General

The Terry Fox Foundation (the Foundation) was established in 1988 to maintain the vision and principles of Terry Fox while raising money for innovative cancer research. In recent years' the Foundation has approved annual Terry Fox runs in many countries around the world and provides funding for cancer research in those countries.

The Foundation is a registered charitable organization under the Income Tax Act and, accordingly, is exempt from income taxes.

The Foundation was established as a Trust on May 26, 1988. On March 12, 1993, the Trustees of the Trust caused the incorporation of an entity known as The Terry Fox Foundation under the laws of Canada. On March 31, 1994, the Trustees transferred all assets and operations of the Trust to the new corporation and the corporation assumed the liabilities of the Trust.

The Terry Fox Research Institute (TFRI) oversees the Foundation's cancer research programs and works with various other organizations that specialize in managing cancer research projects. TFRI has a separate board and is not considered a controlled entity and, accordingly, is not consolidated in these financial statements.

Friends of Terry Fox US (FOTFUS) was established on May 3, 2024, as a non-profit for a charitable, scientific, literary and educational purposes with the meaning of Section 501 (c) (3) of the Internal Revenue Code. FOTFUS has a separate board and is not considered a controlled entity and, accordingly, is not consolidated in these financial statements.

2 Significant accounting policies

These financial statements have been prepared by management in accordance with Canadian accounting standards for not-for-profit organizations in Part III of the Chartered Professional Accountants of Canada (CPA Canada) Handbook – Accounting. The Foundation's significant accounting policies are as follows.

Revenue recognition

The Foundation follows the deferral method of accounting for contributions. Restricted contributions are deferred and recognized as revenue in the period in which the related expenses are incurred or the restrictions are met. Unrestricted contributions are recognized as revenue in the current period, if the amount to be received can be reasonably estimated and collection is reasonably assured.

Revenue from donations, royalties, planned giving and in memoriam gifts received in Canada are recorded in the year received or receivable, if the amount to be received can be reasonably estimated and collection is reasonably assured.

Revenue from the sale of merchandise is recognized when the good is sold, the amount to be received can be estimated and collection is reasonably assured.

Revenue from donations received outside of Canada and used for cancer research in those countries has been combined in these financial statements. The Foundation approves these international activities. Investment income comprises interest and dividends earned on investments. Fair value changes in investments are recognized separately and comprise realized and unrealized gains and losses on investments.

Interest income on short-term and long-term investments is recorded on an accrual basis.

Government grants are recorded as revenue in the fiscal year that the grants are designated to support and when collection is reasonably assured.

Cash and cash equivalents

Cash consists of short-term, highly liquid investments that are subject to insignificant changes in fair value, including cash on hand and deposits with financial institutions that can be withdrawn without prior notice. Cash is carried at cost, which approximates its fair value due to its short-term nature.

International funds held on behalf of the Foundation

The mission and vision of Terry Fox transcends beyond Canadian borders as many nations hold events to raise funds in Terry's name to support and promote cancer research in their countries. The Foundation and TFRI collaborate with local charitable organizations and research institutions to identify cancer research projects and programs for funding. International funds held on behalf of the Foundation represent amounts fundraised internationally and are held on behalf of the Foundation by various international organizations and financial institutions.

Distribution of funds

Research distributions to TFRI support cancer research including translational and discovery projects, research centres and training and the operating costs of managing those research programs. The Foundation recognizes a research distribution expense to TFRI when the transfer of funds has been approved for payment.

The Foundation recognizes international research distribution expenses when an approved research recipient has complied with the conditions of the grant or charitable activities and the Foundation has authorized the release of funds to the grant recipient.

Financial instruments

Financial instruments are recorded at fair value on initial recognition and subsequently at cost or amortized cost, unless management has elected to carry the instruments at fair value. The Foundation has elected to carry its investments at fair value, as there are readily available market prices.

Transaction costs incurred on the acquisition of financial instruments measured subsequently at fair value are expensed as incurred. All other financial instruments are adjusted by transaction costs incurred on acquisition and financing costs, which are amortized using the straight-line method.

Investments

Short-term investments include any term deposits, guaranteed investment certificates, treasury bills, bankers' acceptances, income funds, bonds or equities, with a term to maturity more than 90 days and less than one year. Short-term investments are measured at fair value with subsequent changes to fair value recognized as income in the year.

Long-term investments include any term deposits, guaranteed investment certificates, treasury bills, bankers' acceptances, income funds, bonds or equities, with a term to maturity of more than one year or that are related to internally restricted capital where the board intends to hold them for the long term. Long-term investments are measured at fair value with subsequent changes in fair value recognized as income in the year.

Inventory

Inventory is valued at the lower of cost and net realizable value. Cost is determined by the weighted average method. Net realizable value is the estimated selling price in the ordinary course of business, less estimated cost of completion and selling costs.

Capital and intangible assets

Capital and intangible assets are stated at cost, less accumulated amortization. Donated equipment is recorded at fair market value when received. Amortization is provided using the straight-line method and following annual rates:

Furniture and equipment	5 years
Computer equipment	3 years
Leasehold improvements	5 years
Software customization	5 years

Employee future benefit plans

Effective May 1, 2024, the Foundation entered a new defined contribution plan, DBPlus, with The Colleges of Applied Arts and Technology Pension Plan (CAAT). Prior to that, the Foundation participated in a registered pension plan as an Affiliated Organization of the Registered Pension Plan for the Employees of the Canadian Cancer Society and Affiliated Organizations. In the past, the plan offered both a defined contribution plan and a defined benefit plan.

As of January 1, 2016, the defined benefit provision of the pension plan was closed and no further defined benefit current service contributions were added, only grandfathering existing staff. All new and active members were under the defined contribution provision of the pension plan. As of May 1, 2024, the Registered Pension Plan for the Employees of the Canadian Cancer Society and Affiliated Organizations was terminated.

Foreign currency translation

Monetary assets and liabilities denominated in foreign currencies are translated to Canadian dollars at the prevailing rates of exchange at the statement of financial position date. Revenue and expenses are translated to Canadian dollars at the exchange rates prevailing on the transaction date. Realized and unrealized exchange gains and losses are included in expenses.

Use of estimates

These financial statements have been prepared in accordance with Canadian accounting standards for not-for-profit organizations, which require management estimates and assumptions that affect the reported amount of assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Significant areas requiring management estimates include accrued liabilities and accrued payroll-related liabilities. Actual results could differ from those estimates.

3 Cash and cash equivalents

At year-end, total cash and cash equivalents of $13,387,525 (2025 - $12,473,167) were held primarily to fund operations and anticipated disbursements to TFRI. Cash and cash equivalents is being held in bank accounts generating between 2.45% and 2.95% interest (2025 - between 2.95% and 5.5%).

4 Investments

	2026 $	2025 $
Term deposits and GICs	602,685	590,152
Fixed income fund	30,176,865	39,558,796
Canadian equities fund	8,576,467	7,514,945
Foreign equities fund	31,444,798	25,774,392
Global infrastructure	7,091,327	2,003,883
Global real estate	-	1,943,401
Total investments	77,892,142	77,385,569
Short-term investments	34,560,812	37,385,569
Long-term investments	43,331,330	40,000,000

Investment income and gains comprise of the following:

	2026 $	2025 $
Interest and dividends	3,964,414	4,261,878
Change in unrealized gain on investments	1,854,910	2,523,500
Realized gain (loss) on investments	996,635	474,322
Less: investment management fees	(377,730)	(422,315)
	6,438,229	6,837,385

5 Merchandise inventory

The costs of inventories recognized as an expense and included in cost of merchandise sold amounted to $1,249,102 (2025 - $1,118,908).

6 Accounts receivable and other assets

	2026 $	2025 $
Sales tax receivable	181,540	379,321
Prepaid expenses	371,646	357,796
Accounts receivable and other assets	723,851	442,595
	1,277,037	1,179,712

7 Capital and intangible assets

			2026	2025
	Cost $	Accumulated amortization $	Net $	Net $
Furniture and equipment	37,636	5,964	31,672	9,901
Computer equipment	73,255	14,318	58,937	422
Leasehold improvements	44,326	19,666	24,660	8,463
Software customization	159,832	57,912	101,920	107,509
	315,049	97,860	217,189	126,295

Amortization for the year amounted to $58,443 (2025 – $27,385) and is included in administration expenses.

8 Related party transactions and balances

During the year, the Foundation contributed funds of $37,553,836 (2025 – $29,827,105) to TFRI, which included restricted funding of $5,676,836 (2025 - $5,364,105) towards future expenses under the Marathon of Hope Cancer Center network. TFRI then distributed $26,791,704 (2025 – $26,990,846) of the total funds received to various institutes for cancer research.

Included in accounts payable and accrued liabilities is a balance of $1,533,070 (2025 – $210,018) owing to TFRI relating to the transactions noted above.

Information on the distribution is provided in the audited financial statements of TFRI. The total amount of funding provided to TFRI since its inception in 2007 has been $328,084,797 (unaudited).

TFRI is a not-for-profit organization incorporated by letters patent to promote, advance and fund scientific research into the diagnosis, treatment and prevention of cancer.

During the year, The Foundation received US$154,411 (2025 – NIL) from FOTFUS representing donations from US donors less related bank fees.

Included in accounts receivable and other assets is a balance of CDN$431 (2025 – NIL) due from FOTFUS relating to the transactions noted above.

These transactions are in the normal course of operations and are measured at the exchange amount, which is the amount of consideration established and agreed to by the related parties.

9 Fundraising expenses

As required under Section 7(2) of the Charitable Fundraising Act Regulation of Alberta, the Foundation discloses the expenses incurred for the purpose of soliciting donations, which were $6,986,717 (2025 - $6,308,475). This amount includes total remuneration paid to employees of the Foundation whose principal duties involve fundraising of $3,528,326 (2025 – $3,040,746). These amounts are included as part of the Foundation's operating expenses.

There was no disposition that was equal to or greater than 10% of the gross contributions received from Alberta other than the contribution made to Terry Fox Research Institute as disclosed in Note 8 – Related party transactions and balances.

10 Employee future benefit plans

The Foundation participates in a registered pension plan with a defined contribution component and a defined benefit component as disclosed in note 2.

Defined contribution component

Effective May 1, 2024, the Foundation terminated the registered pension plan and entered into a new defined contribution plan, DBPlus, with The Colleges of Applied Arts and Technology Pension Plan (CAAT). DBPlus is considered a defined contribution plan since the contributions an employer makes are a fixed percentage of earnings, and not dependent on the health of the pension plan.

The Foundation made employer contributions to the pension plan in the amount of $381,772 (2025 – $315,064).

Defined benefit component

Defined benefit obligations are measured using actuarial valuations prepared for accounting purposes, based on the projected benefit method prorated on service (which incorporates estimates of future salary levels, other cost escalation, retirement ages of employees and other actuarial assumptions). The measurement date of the plan assets and defined obligations is January 31. The Registered Pension Plan for the Employees of the Canadian Cancer Society and Affiliated Organizations had an unfunded liability for the defined benefit plan of $19,099,000 as of January 31, 2024, the date of the last actuarial valuation. The unfunded liability is not allocated to individual employers such as the Foundation. Effective May 1, 2024, the plan was terminated, and notices were sent to all members with various options.

The Foundation had 8 employees or retirees eligible under this Plan and made final contributions of $98,600 (2025 – $199,490 including an estimate of $182,000 final liability) to close the defined benefits plan.

Liability for post-retirement benefits

The Foundation participates in a defined benefit post retirement plan offered by the Canadian Cancer Society to certain employees of the Foundation. The liability as allocated to the Foundation was estimated at $35,889 (2025 – $41,499). The most recent actuarial valuation of the post-retirement benefit plan was as of January 31, 2025, and the next required valuation will be as of January 31, 2028. The following assumptions were used:

	2026 %	2025 %
Discount rate	4.6	4.5
Annual health & dental cost trend	3.0 – 6.0	3.0 – 6.0

11 Deferred revenue

Deferred revenue includes cash collected prior to March 31, 2026, designated for a specific investment to occur in next fiscal period of $50,000 (2025 – $111,164 includes cash collected prior to March 31, 2025, designated for the 45th anniversary National Ride of Hope).

12 Internally restricted net asset

In June 2025, the Board of Director internally restricted net assets to ensure approximately two years of funding for TFRI research commitments going forward as a result there was an interfund transfer from unrestricted net assets to internally restricted net assets of $3,331,330 (2025 – NIL). Prior to June 2025, internally restricted net assets consisted of the Research Fund, representing funds received from the Province of BC and the Marathon of Hope Legacy Fund. The funds have been internally restricted by the Board of Directors for future use and are as follows:

	2026 $	2025 $
TFRI research commitment for 2027	25,107,187	-
TFRI research commitment for 2028	18,224,143	-
Research Fund	-	30,000,000
Marathon of Hope Legacy Fund	-	10,000,000
	43,331,330	40,000,000

13 Commitments

Future minimum rental commitments under operating leases on leased premises are as follows:

	$
2027	388,833
2028	382,574
2029	298,881
2030	258,981
2031 and thereafter	607,060
	1,936,329

In addition, a number of the lease commitments for premises and equipment are typically short-term and are subject to annual renewal.

14 Distribution commitments

The Foundation's single mission is to raise funds for cancer research. As such, it seeks advice and management for its cancer research programs from other organizations.

TFRI was established in 2007 to focus on translational cancer research projects and the Foundation committed to provide TFRI funding for its research programs and operations. TFRI is also developing and managing training and new investigator programs on behalf of the Foundation. In October 2009, TFRI was given the responsibility of overseeing all of the Foundation's cancer research programs, working in collaboration with others who also specialize in managing cancer research projects.

Subject to available funds, the Foundation has committed to fund cancer research programs to TFRI over the next 5 years as follows:

	$
2027	25,107,187
2028	18,224,143
2029	10,080,957
2030	3,357,091
2031	1,165,729
	57,935,107

In addition, the Foundation committed to contribute $365,228 (2025 - $444,552) to international cancer research programs as required.

15 Risk management

- Interest rate risk

  The Foundation's fixed income securities are subject to the risk that the values of the investments will fluctuate due to changes in market interest rates. The Foundation mitigates this risk with the advice from their investment advisors whom monitor changes in markets daily and recommend stabilization versus diversification strategies.

- Market risk and foreign currency risk

  The Foundation's foreign equities are subject to the risk that values of the investments will fluctuate due to changes in foreign exchange rates. Returns on the Foundation's investments are subject to risk factors specific to general economic conditions. The market value presents the Foundation's exposure to market/credit risk. The Foundation mitigates this risk by investing in a portfolio that is diversified.

16 Subsequent event

Subsequent to year-end, the Foundation entered into a strategic partnership with Lumira Ventures to establish the Cancer Breakthrough Fund (the "Fund"), a mission-driven venture capital fund focused on investing in companies developing innovative cancer therapies.

The Fund is managed by Lumira Ventures and is intended to support the commercialization of cancer research by combining the Foundation's scientific network with private sector investment expertise. Initial fundraising for the Fund has exceeded its target, with commitments surpassing $30 million and a targeted maximum fund size of $50 million.

The Foundation has committed to a maximum investment of 20% of the total fund up to $10M payable over 4-6 years. Subsequent to year-end, the Foundation has not yet advanced any amounts to the fund.